(Q38148968)

29 August 2017

title

Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity (English)

1 reference

29 August 2017

P Vejpongsa

1

1 reference

29 August 2017

E T H Yeh

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

3 October 2013

1 reference

Clinical Pharmacology & Therapeutics

29 August 2017

published in

1 reference

29 August 2017

volume

95

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

45-52

1 reference

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Supercoiling of the DNA template during transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Qualitative and quantitative aspects of intercalator-induced DNA strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Doxorubicin-induced cardiac mitochondrionopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Transcriptional control of cardiac fuel metabolism and mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Telomere dysfunction induces metabolic and mitochondrial compromise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Breast cancer and other second neoplasms after childhood Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

‘Daunomycin’, a New Antibiotic of the Rhodomycin Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

Rubidomycin. A new agent active in the treatment of acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Assessment of anthracycline cardiomyopathy by endomyocardial biopsy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Topoisomerase II Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Cardiovascular effects in childhood cancer survivors treated with anthracyclines

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.201

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.201

1 reference

29 August 2017

1 reference